GLP-1 Drugs Are One of Only Two Therapies That Improve Both Quality of Life and Exercise Capacity in Heart Failure | Research

The takeaway

In a meta-analysis of heart failure drug trials, only GLP-1/GIP agonists and IV iron improved both quality of life and exercise capacity, outperforming SGLT2 inhibitors, ARNIs, and other standard therapies on patient-centered outcomes.

2 of 8 drug classes
improved both quality of life and exercise capacity in heart failure — GLP-1/GIP agonists and IV iron, while many standard therapies improved neither

What the researchers found

GLP-1 or GLP-1/GIP agonists significantly improved both KCCQ quality of life scores and 6-minute walking distance compared to placebo in heart failure patients. IV iron was the only other therapy to achieve improvements on both outcomes.

SGLT2 inhibitors improved KCCQ scores but not 6-minute walking distance. MRA, ARNI, vericiguat, and ivabradine showed no significant differences in KCCQ scores versus placebo/control. Beta-blockers, ARNI, MRA, SGLT2 inhibitors, and ivabradine showed no significant improvement in 6-minute walking distance.

Why it matters

Heart failure treatment has traditionally focused on mortality and hospitalization reduction. But patients often rank feeling better and being able to exercise as equally or more important. This meta-analysis reveals a striking gap: many drugs that save lives don't measurably improve how patients feel day-to-day. GLP-1 agonists' ability to improve both quality of life and functional capacity adds a compelling patient-centered argument for their use in heart failure.

How the study worked

Meta-analysis of randomized controlled trials in ambulatory (outpatient) heart failure. Eight drug classes were analyzed: IV iron, beta-blockers, SGLT2 inhibitors, ARNI, MRA, vericiguat, ivabradine, and GLP-1/GIP agonists. Co-primary outcomes were KCCQ scores (quality of life) and 6-minute walking distance (exercise capacity).

What this study cannot tell us

The meta-analysis combines trials with different heart failure populations, definitions, and treatment durations. KCCQ and 6MWD may not have been primary outcomes in the underlying trials, potentially introducing reporting bias. The number of GLP-1/GIP agonist trials in heart failure is still relatively small compared to established drug classes. The analysis does not account for differences in mortality benefit across drug classes.

How to read the evidence

This is a meta-analysis of randomized controlled trials published in JACC Advances, representing high-level evidence. The inclusion of multiple drug class comparisons using standardized patient-centered outcomes provides robust comparative effectiveness data.

When this study was published

Published in 2025, this meta-analysis incorporates the latest trial data on heart failure pharmacotherapy, including recent GLP-1/GIP agonist trials.

The bigger picture

This meta-analysis reframes the heart failure drug hierarchy through a patient-centered lens. While mortality data drives guideline recommendations, patient-reported outcomes increasingly influence clinical decision-making. The finding that GLP-1/GIP agonists excel on patient-centered measures — despite being relatively new to heart failure management — could accelerate their integration into treatment guidelines and clinical practice.

Questions still open

Should patient-centered outcomes like KCCQ and 6MWD receive more weight in heart failure treatment guidelines?
Does the GLP-1 agonist benefit on quality of life come from weight loss, direct cardiac effects, or both?
Could combining GLP-1 agonists with IV iron maximize patient-centered outcomes in heart failure?

Common questions

Which heart failure drugs make patients feel the best?

This meta-analysis found that GLP-1/GIP agonists and IV iron were the only two drug classes that improved both quality of life and exercise capacity. Many standard drugs like beta-blockers and ARNIs, while they reduce mortality, did not significantly improve how patients feel day-to-day.

Should heart failure patients ask about GLP-1 drugs?

These findings suggest it's worth discussing with your cardiologist, especially if improving daily quality of life and physical function are priorities. GLP-1/GIP agonists showed benefits on patient-centered outcomes that most other heart failure drugs did not, though they should be used alongside — not instead of — proven life-saving therapies.

Read the original research

Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials.

JACC. Advances, 4(12 Pt 2), 102356

View on PubMed ↗Publisher’s paper ↗

Citation

Kido, Kazuhiko; Hashiguchi, Masayuki; Guglin, Maya. (2025). Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials.. JACC. Advances, 4(12 Pt 2), 102356. https://doi.org/10.1016/j.jacadv.2025.102356